文献速递多重用药衰弱、肌少症与跌倒

衰弱老年人减药优化健康结局:Opti-med双盲安慰剂对照随机试验

Deprescribing to optimise health outcomes for frail older people: a double-blind placebo-controlled randomised controlled trial-outcomes of the Opti-med study.
PubMed 文献 · Age Ageing · 2023-01-01

三臂随机对照试验纳入303名居住于养老机构的65岁以上老年人,比较盲法干预、开放干预与盲法对照的减药效果。减药与12个月内每人用药总数显著减少相关,盲法干预组减少2.7种药(95%CI -3.5,-1.9),开放干预组减少2.3种药(95%CI -3.1,-1.4),对照组减少0.3种药(95%CI -1.0,0.4,P=0.053)。减药未伴随按需用药数量显著增加,盲法干预组(HR 0.93,95%CI 0.50,1.73,P=0.83)和开放干预组(HR 1.47,95%CI 0.83,2.61,P=0.19)死亡率与对照组无显著差异。

要点

  • 盲法干预组12个月内每人用药总数减少2.7种(95%CI -3.5,-1.9),开放干预组减少2.3种(95%CI -3.1,-1.4)。
  • 减药未导致按需用药数量显著增加。
  • 盲法干预组死亡风险HR 0.93(95%CI 0.50,1.73),开放干预组HR 1.47(95%CI 0.83,2.61),与对照组无显著差异。

核心结论

  • 基于方案的减药可实现每人减少2至3种药物。
  • 预设招募目标未达到,减药对生存和其他临床结局的影响仍不确定。

研究设计与样本

  • 三臂(开放干预、盲法干预、盲法对照)随机对照试验,纳入303名65岁以上居住于养老机构的老年人,预设招募目标为954人。
  • 盲法组将目标减药药物装入胶囊,在减药(盲法干预)或继续用药(盲法对照)期间保持盲态;第三组为开放干预组,对目标药物进行非盲减药。

主要发现

  • 参与者76%为女性,平均年龄85.0±7.5岁。
  • 12个月内每人用药总数变化:盲法干预组减少2.7种(95%CI -3.5,-1.9),开放干预组减少2.3种(95%CI -3.1,-1.4),对照组减少0.3种(95%CI -1.0,0.4,P=0.053)。
  • 减药常规药物未伴随按需用药数量显著增加。
  • 与对照组相比,盲法干预组死亡率HR 0.93(95%CI 0.50,1.73,P=0.83),开放干预组HR 1.47(95%CI 0.83,2.61,P=0.19),均无显著差异。

临床怎么用

  • 对养老机构衰弱老年人可实施基于方案的减药,实现每人减少2至3种药物。
  • 减药过程中需监测按需用药数量变化及死亡等临床结局。

局限性

  • 预设招募目标未达到,减药对生存和其他临床结局的影响仍不确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: potentially harmful polypharmacy is very common in older people living in aged care facilities. To date, there have been no double-blind randomised controlled studies of deprescribing multiple medications. METHODS: three-arm (open intervention, blinded intervention and blinded control) randomised controlled trial enrolling people aged over 65 years (n = 303, noting pre-specified recruitment target of n = 954) living in residential aged care facilities. The blinded groups had medications targeted for deprescribing encapsulated while the medicines were deprescribed (blind intervention) or continued (blind control). A third open intervention arm had unblinded deprescribing of targeted medications. RESULTS: participants were 76% female with mean age 85.0 ± 7.5 years. Deprescribing was associated with a significant reduction in the total number of medicines used per participant over 12 months in both intervention groups (blind intervention group -2.7 medicines, 95% CI -3.5, -1.9, and open intervention group -2.3 medicines; 95% CI -3.1, -1.4) compared with the control group (-0.3, 95% CI -1.0, 0.4, P = 0.053). Deprescribing regular medicines was not associated with any significant increase in the number of 'when required' medicines administered. There were no significant differences in mortality in the blind intervention group (HR 0.93, 95% CI 0.50, 1.73, P = 0.83) or the open intervention group (HR 1.47, 95% CI 0.83, 2.61, P = 0.19) compared to the control group. CONCLUSIONS: deprescribing of two to three medicines per person was achieved with protocol-based deprescribing during this study. Pre-specified recruitment targets were not met, so the impact of deprescribing on survival and other clinical outcomes remains uncertain.

来源:Age Ageing,查看原文。版权归原作者所有。

引用

  1. Etherton-Beer C, Page A, Naganathan V, et al. Deprescribing to optimise health outcomes for frail older people: a double-blind placebo-controlled randomised controlled trial-outcomes of the Opti-med study. Age Ageing. 2023. PMID: 37247404. doi:10.1093/ageing/afad081

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。